Table 1.

Patient characteristics and clinical response

PatientAge (y)SexPrimaryPalliative chemotherapySites of disease at screeningTrial: cyclesBest CT responseSerum tumor antigen changeOS (mo)
141MEECFL, N, liver, lung1PDIncrease2.73
249MEECFL2SDStable5.07
363MGEJCFL, N1PDDecrease10.17
437FGMCXDuodenal mass, ascites, peritoneal, pelvic2SDStable12.20
555MECFL, N, liver, lung, bone1PDIncrease1.70
639MGECF, ECXL, N1PDIncrease3.63
763MGEJCFL, N, lung2PDIncrease7.27
843FGECX, D/IL, omental, serosal, ascites1PD12.03
957MGC/TS1L, N, pleural effusion, ascites1PD4.27
1075FGMCXL, N, liver1PDIncrease4.60
1149MEECFL, adrenal, chest wall, muscle1PDIncrease2.20
1267MEECXL, N, liver, lung, adrenal, pleural, bone11PRDecrease32.70+
1375MGEJMCXL, N, lung, pleural effusion1*Increase3.73
1461FGECF, MCFN, splenic1PDDecrease17.93
1568MGEJECXL, N, liver, lung2PDIncrease17.10
1641MGEJCFL, N1PDIncrease4.83
1762MEMCXL (pericardium and diaphragm)2SDIncrease12.83
1853MGEJECFL, liver, chest wall1PDIncrease4.70

Abbreviations: D/I, Docetaxel/Irinotecan; OS, overall survival; ES, esophageal; G, gastric; GEJ, gastroesophageal junction; E, epirubicin; C, cisplatin; F, 5-fluorouracil; M, mitomycin; X, capecitabine; TS1, an oral 5-fluorouracil derivative; L, local; N, lymph node; PD, progressive disease; SD, stable disease; PR, partial response; +, patient still alive.